Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 8Myeloproliferative Disorders 3Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myelodysplastic Syndromes 1Leukemia, Monocytic, Acute 1

Interventions

ruxolitinib 6fludarabine phosphate 2Whole-Body Irradiation 2Tacrolimus 2Specimen Handling 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Injections 2Cyclophosphamide 2Busulfan 2Biopsy 2venetoclax 1veliparib 1piperine 1pevonedistat 1iadademstat 1fludarabine 1fedratinib 1demethoxycurcumin 1decitabine and cedazuridine drug combination 1bomedemstat 1Transplantation 1Topotecan 1Stem Cell Transplantation 1Sirolimus 1Resistance Training 1Radiotherapy 1N(4)-oleylcytosine arabinoside 1Methotrexate 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thrombocythemia, Essential × Liposomes × 90 days × Clear all
NCT03878199 2026-04-24

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
12 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡